On this page
- What a literature search actually returns
- Why that substitution does not work
- What psoriasis-specific work exists
- Psoriasis is not an untreated disease
- How psoriasis severity is actually measured
- Why it is marketed anyway
- Psoriatic arthritis is a separate question
- What this page is not saying
- Questions worth asking
- Frequently asked questions
- Requesting a medical evaluation
Psoriasis is widely advertised as a stem cell indication, and searching the literature for it returns something unexpected: nearly every trial is in a different skin disease. Stem cell therapy for psoriasis rests almost entirely on atopic dermatitis research, and the two conditions are not the same.
What a literature search actually returns
Searching for cell therapy trials in psoriasis returns a list dominated by atopic dermatitis: a phase 2 placebo-controlled trial of adipose-derived cells — Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial — and a systematic review of human trials — The Potential Role of Mesenchymal Stem Cell Therapy for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Human Clinical Trials.
Earlier work followed the same pattern — Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies and Phase 1/2 trials of human bone marrow-derived clonal mesenchymal stem cells for treatment of adults with moderate to severe atopic dermatitis.
Four studies, all in atopic dermatitis. None of them is a psoriasis trial, and a clinic quoting “trials in inflammatory skin disease” is usually quoting these.
Why that substitution does not work
Atopic dermatitis and psoriasis are both inflammatory skin diseases and they are driven by different immune pathways. The drugs that work well in one frequently do nothing in the other, which is the clearest possible evidence that the mechanisms differ.
Biologic drugs make the point precisely: agents targeting interleukin-17 and interleukin-23 transformed psoriasis treatment and are not the treatments used for atopic dermatitis, which responds to a different set of targets.
A cell therapy acting on inflammation generally cannot be assumed to act on both. That assumption is exactly what the substitution requires.
What psoriasis-specific work exists
One study has tested a topical preparation of cell secretome with hyaluronic acid in psoriasis vulgaris — Novel sponge formulation of mesenchymal stem cell secretome and hyaluronic acid: a safe and effective topical therapy for Psoriasis vulgaris.
Note what that is. A topical product containing what cells secrete, applied to the skin. Not an infusion, and not cells.
A single small study of a topical preparation is not a basis for intravenous cell therapy, and it is the only psoriasis-specific entry the search returns.
Psoriasis is not an untreated disease
This is one of the great success stories of modern immunology. Biologic drugs have taken a substantial proportion of patients to completely or almost completely clear skin in large randomised trials.
Those drugs are available, their evidence is enormous, and their long-term safety is tracked in registries covering many thousands of patients.
Against that, an infusion with no psoriasis trial behind it is a poor exchange. This is not a condition where the established options have run out.
How psoriasis severity is actually measured
Dermatology trials use a scored index combining the redness, thickness and scaling of plaques with the proportion of body surface affected. Results are reported as the share of patients achieving a seventy-five or ninety per cent reduction in that score.
Those thresholds exist because they are hard to reach by chance and hard to fake. Modern biologic drugs are judged against them, and that is why their results can be compared across trials run by different groups in different countries.
Nothing sold as cell therapy for psoriasis reports outcomes in those terms. Photographs, patient satisfaction and “visible improvement” are not the same currency, and a reader who does not know the standard exists cannot tell that it is missing.
If a clinic offers this treatment, asking what score it achieved and over what period is a fair question with a clear right answer.
The same applies to the trials quoted from atopic dermatitis, which use their own severity index. Those studies report against a recognised standard; the treatment being sold on their strength generally does not.
Why it is marketed anyway
Psoriasis is visible, chronic, and distressing, and it fluctuates. Those four features together make it an easy condition to appear to treat.
Psoriasis improves with sunlight, and clears in many people over a warm holiday. A treatment given in Thailand in the sunshine is competing with a well-documented natural effect.
Stress, infection and season all shift disease activity. A before-and-after photograph across a two-week trip establishes nothing.
Psoriatic arthritis is a separate question
Around a third of people with psoriasis develop joint involvement, and that is a different problem with different consequences — joint damage can be permanent.
It is also better addressed by the rheumatology pathway, with drugs that treat both skin and joints. Rheumatoid arthritis covers the related evidence in inflammatory joint disease.
If joints are involved, that should be assessed properly rather than folded into a skin treatment package.
What this page is not saying
It is not saying cell therapy could never work in psoriasis. The mechanism is not absurd and trials could be run.
It is saying that as of now they have not been, and that the evidence being used to sell it was collected in a different disease.
The limits of current evidence covers the general shape of this problem across the field.
Questions worth asking
- Which trial in psoriasis specifically supports this?
- If the answer names atopic dermatitis, why is that relevant to my disease?
- Have I been assessed for biologic treatment by a dermatologist?
- Are my joints involved, and has that been checked?
The autoimmune overview places this among conditions where evidence does exist, and the patient journey describes what an honest assessment includes.
Frequently asked questions
Are there stem cell trials in psoriasis?
One small study of a topical secretome preparation. The randomised trials usually quoted were conducted in atopic dermatitis.
Is atopic dermatitis close enough?
No. The two diseases run on different immune pathways, which is why the drugs that work in one often do nothing in the other.
My skin cleared on holiday. Was that the treatment?
Psoriasis improves with sunlight in many people. A two-week trip to a sunny country is a strong confounder.
What should I try instead?
Dermatology assessment for established treatment. Biologic drugs have taken many patients to clear or nearly clear skin in large randomised trials.
What about my joints?
Psoriatic arthritis affects around a third of people with psoriasis and can cause permanent damage. It needs separate assessment.
Could it work eventually?
Possibly. The mechanism is not implausible and trials could be run. They have not been, and that is the whole of the current position.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.